After signing up, you'll start to receive regular news updates from us.
Motif Bio Receives Award from Cystic Fibrosis Foundation
Complete the form below to unlock access to ALL audio articles.
Motif Bio® plc, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has received an award from the Cystic Fibrosis Foundation to fund important in vitro testing that will help to advance the development of iclaprim for the treatment of lung infections in patients with cystic fibrosis (CF). This is the first award that the Company has received from the Cystic Fibrosis Foundation.
David Huang, MD, PhD, Chief Medical Officer of Motif Bio, said: “We are delighted to have received this award from the Cystic Fibrosis Foundation, a leader in the search for a cure for cystic fibrosis. Patients with cystic fibrosis, especially in the later stages of lung disease, are often infected with multidrug resistant bacteria that severely limit treatment options. The grant will advance the work we are doing to further elucidate iclaprim’s ability to inhibit the most problematic bacteria, including multidrug resistant bacteria, that are common in patients with cystic fibrosis.”
Bacterial pathogens that infect the airways of people with CF often exhibit broad-spectrum resistance to currently available antibiotics. Many of these bacteria are inherently resistant to specific classes of antibiotics. Side effects such as nephrotoxicity and peripheral neuropathy have been reported with currently available Gram-positive antibiotics used to treat lung infections in patients with CF. In the in vitro study to be conducted with the $120,000 award from the Cystic Fibrosis Foundation, the activity of iclaprim against various strains of Burkholderia, Stenotrophomonas and Achromobacter will be determined. These bacteria are frequently present in the airways of patients with CF and many strains are resistant to common antibiotics.
Iclaprim has been studied in an animal model of chronic pulmonary methicillin resistant Staphylococcus aureus (MRSA) infection, which mimics the pathophysiology observed in the lungs of patients with CF. These data were published in December 2017 in the European Journal of Clinical Microbiology & Infectious Diseases (Huang, D.B., Morrissey, I., Murphy, T. et al. Eur J Clin Microbiol Infect Dis (2017).
This article has been republished from materials provided by Motif Bio. Note: material may have been edited for length and content. For further information, please contact the cited source.
